News | ARLG

ARLG at ESCMID 2026
Every year, the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) brings together experts in infectious diseases and clinical microbiology, including many ARLG members. ESCMID Global 2026 is being held on April 17-21 in Munich, Germany, with live streaming of sessions for virtual attendees. Check out the list below of ARLG ...
Read more
TATFAR Manuscript Highlights ARLG Phage Research
A new manuscript in Nature Communications discusses the global effort to support phage therapy and features ARLG’s research along with other collaborative initiatives. “Considerations and perspectives on phage therapy from the Transatlantic Taskforce on Antimicrobial Resistance (TATFAR)” details discussions from key meetings in 2023 and 2024 where experts and regulatory authorities from the United States, ...
Read more
Dr. Lodise Receives ASHP Foundation Award
Thomas Lodise, PharmD, PhD, who serves as the ARLG Network’s Pharmacokinetic Scientific Lead, received the 2025 Literature Award for Sustained Contributions from the American Society of Health-System Pharmacists (ASHP) Foundation. With over 250 peer-reviewed articles, Dr. Lodise has made significant contributions to biomedical literature on treatments for antimicrobial resistant (AMR) infections. Congratulations to Dr. Lodise for ...
Read more
ARLG Experts Share Strategies to Combat Antibacterial Resistance
ARLG Co-Principal Investigator, Vance Fowler, MD, and Helen Boucher, MD, ARLG Executive Committee Member and Innovations Working Group Chair, shared their insights on the current state of antimicrobial resistance (AMR) in a recent article published by the Association of American Medical Colleges (AAMC). The article, “Where are we in the battle against antibiotic-resistant infections?,” also ...
Read more

ARLG in the News

As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers’ Interest, JAMA Network, February 22, 2023

Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection, January 12, 2023

Study Evaluates Biomarker to Help Curb Unnecessary Antibiotic Use, December 13, 2022

NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins, October 4, 2022

Dr. Robin Patel Selected for 2022 Hamao Umezawa Memorial Award, March 8, 2022

Local VA Infectious Disease Expert Selected to Lead Emerging Infectious Diseases Response, March 2, 2022

Duke doctor: Superbugs are the next pandemic. What the US must do to combat them. Op-ed, Raleigh News & Observer, Charlotte Observer, Durham Herald-Sun. January 20, 2022

Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study, November 2, 2021

Carbapenem-resistant Enterobacterales in the USA, March 6, 2020

Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study, March 6, 2020

NIH Renews Funding for the Antibacterial Resistance Leadership Group, NIAID, December 13, 2019

Research Network Based at DCRI Awarded up to $102.5M for Work on Antibacterial Resistance, DCRI, December 13, 2019

Duke Clinical Research scores $102.5M federal award for its work on antibacterial resistance, WRAL TechWire, December 2019.

Duke Clinical Research Institute lands $100M+ federal contract, Triangle Business Journal, December 2019.

Licensing Nucleic Acid Amplification Tests for Extragenital Gonorrhea and Chlamydia: Innovative Science and a Call to Arms. Clinical Infectious Diseases editorial authors praise the ARLG MASTER-GC study for its clinical relevance and collaborative approach to the development of diagnostics. November 2019.

Reviewing data collected by the ARLG, FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea, FDA, May 23, 2019

The ARLG and COMBACTE join forces to create gloabal alliance against antibiotic resistance, DCRI, April 13, 2019